NBIX - Neurocrine Biosciences

-

$undefined

N/A

(N/A)

Neurocrine Biosciences NASDAQ:NBIX Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, Neurocrine Biosciences has specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems.

Location: 12780 El Camino Real, California, 92130-2042, US | Website: www.neurocrine.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

13.92B

Cash

1.228B

Avg Qtr Burn

N/A

Short % of Float

3.35%

Insider Ownership

0.99%

Institutional Own.

95.27%

Qtr Updated

09/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

INGREZZA (valbenazine) Details
Chorea, Huntington's disease, Dyskinesia

Approved

Quarterly sales

INGREZZA (valbenazine) Details
Huntington's disease, Dyskinesia

Approved

Quarterly sales

Approved

Quarterly sales

INGREZZA (valbenazine) Details
Huntington's disease, Chorea

Approved

Quarterly sales

Valbenazine Details
Psychiatric disorder, Schizophrenia

Phase 3

Data readout

Valbenazine Details
Neurological disorder, Dyskinesia , Cerebral Palsy

Phase 3

Data readout

Phase 3

Initiation

Phase 2

Data readout

Chronocort® (Efmody) Details
Adrenal Insufficiency

Phase 2

Update

NBI-1065846 Details
Major depressive disorder

Phase 2

Update

NBI-1065845 Details
Major depressive disorder

Phase 2

Update

Efmody Details
Congenital adrenal hyperplasia

Phase 2

Update

NBI-921352 Details
Focal Onset Seizures

Phase 2

Update

NBI-1117567 Details
Neurological disorder, Psychiatric disorder

Phase 1

Data readout

NBI-1076986 Details
Parkinson's disease, Dystonia (Blepharospasm)

Phase 1

Data readout

Phase 1

Data readout

NBI-1065890 Details
Neurological disorder

Phase 1

Data readout

Luvadaxistat Details
Psychiatric disorder, Schizophrenia

Failed

Discontinued